Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245408 | 0.82 | SMN1; SMN2 (0.42) | CASP3ALDH1A1GAASMN1; SMN2MGLL | |
| SCHEMBL558780 | 0.81 | CASP3 (0.43) | CASP3ALDH1A1GAASMN1; SMN2MGLL | |
| SCHEMBL1244369 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1GAASMN1; SMN2MGLLHPGD | |
| SCHEMBL1244543 | 0.81 | MEN1 (0.42) | CASP3ALDH1A1GAASMN1; SMN2MGLL | |
| SCHEMBL1244354 | 0.81 | POLB (0.50) | CASP3ALDH1A1GAATP53 | |
| SCHEMBL1243015 | 0.80 | ALOX15 (0.47) | ALDH1A1GAAMGLL | |
| SCHEMBL1244960 | 0.77 | GAA (0.61) | GAAMGLL | |
| SCHEMBL1244446 | 0.77 | MGLL (0.43) | CASP3ALDH1A1GAASMN1; SMN2MGLL | |
| SCHEMBL1242936 | 0.77 | GAA (0.51) | ALDH1A1GAASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL1245056 | 0.74 | TRPA1 (0.52) | CASP3GAAMGLLMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2024380-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | Adenosine Therapeutics, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136817-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | CASP3 4138/4885ALDH1A1 830/4885GAA 3633/4885 |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | CASP3 4138/4885ALDH1A1 830/4885GAA 3633/4885 |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | CASP3 4138/4885ALDH1A1 830/4885GAA 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.